PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years
Phase 2
Completed
- Conditions
- Encephalitis, Tick-borne
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 615
- Registration Number
- NCT00161850
- Locations
- π¦πΉ
Grieskirchner Strasse 17, Wels, Austria
π©πͺNeuschwanstein Strasse 5, Augsburg, Germany
π©πͺMarktplatz 33, Bad Saulgau, Germany
Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD
Phase 4
Completed
- Conditions
- Cardiovascular Diseases
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8600
- Registration Number
- NCT00159835
- Locations
Pfizer Investigational Site
Voriconazole For Chronic Bronchopulmonary Aspergillosis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2010-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT00159822
- Locations
- π«π·
Pfizer Investigational Site, Suresnes, France
Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents
Phase 3
Completed
- Conditions
- Growth Hormone Deficiency
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-07-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT00156143
Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia
Phase 2
Terminated
- Conditions
- Pain
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-03-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 315
- Registration Number
- NCT00159640
- Locations
Pfizer Investigational Site
Effect Of A Treatment Optimization Program To Improve Satisfaction With Viagra
Phase 4
Completed
- Conditions
- Impotence
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8000
- Registration Number
- NCT00159848
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
Phase 4
Completed
- Conditions
- Acromegaly
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00151437
- Locations
- π¨π¦
Pfizer Investigational Site, Montreal, Quebec, Canada
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
Terminated
- Conditions
- Familial Adenomatous Polyposis (FAP)
- Interventions
- Other: Routine Medical Care
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 68
- Registration Number
- NCT00151476
- Locations
- πͺπΈ
Pfizer Investigational Site, Barcelona, Spain
12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation
Phase 2
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00150228
- Locations
- πΊπΈ
Pfizer Investigational Site, Madison, Wisconsin, United States
A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation
Phase 2
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 625
- Registration Number
- NCT00150241
- Locations
- πΊπΈ
Pfizer Investigational Site, Morgantown, West Virginia, United States
Β© Copyright 2025. All Rights Reserved by MedPath